Literature DB >> 28609657

ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer.

Kiran Mahajan1, Pavani Malla2, Harshani R Lawrence3, Zhihua Chen4, Chandan Kumar-Sinha5, Rohit Malik5, Sudhanshu Shukla5, Jongphil Kim6, Domenico Coppola7, Nicholas J Lawrence8, Nupam P Mahajan9.   

Abstract

The androgen receptor (AR) is critical for the progression of prostate cancer to a castration-resistant (CRPC) state. AR antagonists are ineffective due to their inability to repress the expression of AR or its splice variant, AR-V7. Here, we report that the tyrosine kinase ACK1 (TNK2) phosphorylates histone H4 at tyrosine 88 upstream of the AR transcription start site. The WDR5/MLL2 complex reads the H4-Y88-phosphorylation marks and deposits the transcriptionally activating H3K4-trimethyl marks promoting AR transcription. Reversal of the pY88-H4 epigenetic marks by the ACK1 inhibitor (R)-9bMS-sensitized naive and enzalutamide-resistant prostate cancer cells and reduced AR and AR-V7 levels to mitigate CRPC tumor growth. Thus, a feedforward ACK1/pY88-H4/WDR5/MLL2/AR epigenetic circuit drives CRPC and is necessary for maintenance of the malignant state.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACK1; AR; AR-V7; TNK2; castration resistance; enzalutamide; epigenetics; histone; prostate cancer; small-molecule inhibitor; tyrosine phosphorylation

Mesh：

Substances：

Year:  2017        PMID： 28609657      PMCID： PMC5512571          DOI： 10.1016/j.ccell.2017.05.003

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  41 in total

Review 1.  Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer.

Authors:  Lunawati L Bennett; April Ingason
Journal:  Ann Pharmacother       Date:  2014-01-23       Impact factor: 3.154

Review 2.  Androgen receptor signaling in androgen-refractory prostate cancer.

Authors:  M E Grossmann; H Huang; D J Tindall
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

3.  Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox.

Authors:  Nupam P Mahajan; Young E Whang; James L Mohler; H Shelton Earp
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

6.  Functional analysis of Sox8 and Sox9 during sex determination in the mouse.

Authors:  Marie-Christine Chaboissier; Akio Kobayashi; Valerie I P Vidal; Susanne Lützkendorf; Henk J G van de Kant; Michael Wegner; Dirk G de Rooij; Richard R Behringer; Andreas Schedl
Journal:  Development       Date:  2004-03-31       Impact factor: 6.868

7.  An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Authors:  Manav Korpal; Joshua M Korn; Xueliang Gao; Daniel P Rakiec; David A Ruddy; Shivang Doshi; Jing Yuan; Steve G Kovats; Sunkyu Kim; Vesselina G Cooke; John E Monahan; Frank Stegmeier; Thomas M Roberts; William R Sellers; Wenlai Zhou; Ping Zhu
Journal:  Cancer Discov       Date:  2013-07-10       Impact factor: 39.397

8.  Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.

Authors:  Daniel E Spratt; Michael J Evans; Brian J Davis; Michael G Doran; Man Xia Lee; Neel Shah; John Wongvipat; Kathryn E Carnazza; George G Klee; William Polkinghorn; Donald J Tindall; Jason S Lewis; Charles L Sawyers
Journal:  Cancer Res       Date:  2015-10-02       Impact factor: 12.701

9.  Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.

Authors:  Lina Gao; Jacob Schwartzman; Angela Gibbs; Robert Lisac; Richard Kleinschmidt; Beth Wilmot; Daniel Bottomly; Ilsa Coleman; Peter Nelson; Shannon McWeeney; Joshi Alumkal
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

10.  Overcoming mutation-based resistance to antiandrogens with rational drug design.

Authors:  Minna D Balbas; Michael J Evans; David J Hosfield; John Wongvipat; Vivek K Arora; Philip A Watson; Yu Chen; Geoffrey L Greene; Yang Shen; Charles L Sawyers
Journal:  Elife       Date:  2013-04-09       Impact factor: 8.140
View more
  44 in total

1.  Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.

Authors:  Shidong Lv; Haoran Wen; Xiongwei Shan; Jianhua Li; Yaobin Wu; Xinpei Yu; Wenhua Huang; Qiang Wei
Journal:  Epigenetics       Date:  2019-06-28       Impact factor: 4.528

2.  Prostate cancer: Epigenetic AR regulation.

Authors:  Clemens Thoma
Journal:  Nat Rev Urol       Date:  2017-07-04       Impact factor: 14.432

Review 3.  EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.

Authors:  Rama Soundararajan; Anurag N Paranjape; Sankar Maity; Ana Aparicio; Sendurai A Mani
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-07-05       Impact factor: 10.680

4.  Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.

Authors:  Claire L Soave; Tracey Guerin; Jinbao Liu; Q Ping Dou
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264

Review 5.  The complex activities of the SET1/MLL complex core subunits in development and disease.

Authors:  Hao Jiang
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2020-04-15       Impact factor: 4.490

6.  ACK1 upregulated the proliferation of head and neck squamous cell carcinoma cells by promoting p27 phosphorylation and degradation.

Authors:  Hsuan-Hsiang Peng; Hao-Chin Yang; Darius Rupa; Chun-Han Yen; Ya-Wen Chiu; Wei-Jia Yang; Fuh-Jinn Luo; Ta-Chun Yuan
Journal:  J Cell Commun Signal       Date:  2022-03-05       Impact factor: 5.782

7.  Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer.

Authors:  Duy T Nguyen; Wei Yang; Kiran Mahajan; Arun Renganathan; Cody Weimholt; Duminduni H Angappulige; Thanh Nguyen; Robert W Sprung; Gerald L Andriole; Eric H Kim; Nupam P Mahajan
Journal:  Clin Cancer Res       Date:  2022-09-15       Impact factor: 13.801

8.  SHP-1 dephosphorylates histone H2B to facilitate its ubiquitination during transcription.

Authors:  Prajakta Tathe; K V S Rammohan Chowdary; Krushna Chandra Murmu; Punit Prasad; Subbareddy Maddika
Journal:  EMBO J       Date:  2022-08-08       Impact factor: 14.012

9.  Proximity-Dependent Biotinylation to Elucidate the Interactome of TNK2 Nonreceptor Tyrosine Kinase.

Authors:  Raiha Tahir; Anil K Madugundu; Savita Udainiya; Jevon A Cutler; Santosh Renuse; Li Wang; Nicole A Pearson; Christopher J Mitchell; Nupam Mahajan; Akhilesh Pandey; Xinyan Wu
Journal:  J Proteome Res       Date:  2021-08-24       Impact factor: 4.466

10.  Pseudogene ACTBP2 increases blood-brain barrier permeability by promoting KHDRBS2 transcription through recruitment of KMT2D/WDR5 in Aβ1-42 microenvironment.

Authors:  Qianshuo Liu; Xiaobai Liu; Defeng Zhao; Xuelei Ruan; Rui Su; Xiuli Shang; Di Wang; Chunqing Yang; Yixue Xue
Journal:  Cell Death Discov       Date:  2021-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.